CVS Caremark Reverses, Restores Zepbound Coverage Amid Patient Backlash

CVS Caremark will reinstate Lilly’s weight‑loss drug Zepbound on its standard formulary by Oct. 1 after patient backlash over its prior removal, which had pressured some users to switch to Wegovy. The change, affecting about 25–30 million people, does not guarantee coverage for all employer plans but may widen access; Lilly says some private plans could offer as little as a $25 copay. Lilly’s Foundayo will also be added to the formulary starting Monday. Zepbound’s list price is around $1,086 per month before discounts, and a related class‑action lawsuit over the initial formulary decision remains active. Express Scripts and Optum Rx already cover Zepbound.